TACE: a new target in epidermal growth factor receptor dependent tumors
- PMID: 17608729
- DOI: 10.1111/j.1432-0436.2007.00198.x
TACE: a new target in epidermal growth factor receptor dependent tumors
Abstract
Soluble proteins play vital roles in mediating intercellular communication. Many of these proteins are secreted as freely soluble molecules, but an important class of signaling proteins are first synthesized and presented at the cell surface as transmembrane precursor proteins. Unlike classically secreted proteins, many of these molecules are regulated at an additional level, requiring proteolytic cleavage for activity. This review focuses on a subset of these proteins, which are cleaved by tumor necrosis factor alpha-converting enzyme (TACE)/ADAM17, and on their role in cancer.
Similar articles
-
Tackling EGFR signaling with TACE antagonists: a rational target for metalloprotease inhibitors in cancer.Expert Opin Ther Targets. 2007 Oct;11(10):1287-98. doi: 10.1517/14728222.11.10.1287. Expert Opin Ther Targets. 2007. PMID: 17907959 Review.
-
ADAM17, shedding, TACE as therapeutic targets.Pharmacol Res. 2013 May;71:19-22. doi: 10.1016/j.phrs.2013.01.012. Epub 2013 Feb 13. Pharmacol Res. 2013. PMID: 23415892 Review.
-
Multiple shRNA-mediated knockdown of TACE reduces the malignancy of HeLa cells.Cell Biol Int. 2009 Feb;33(2):158-64. doi: 10.1016/j.cellbi.2008.10.008. Epub 2008 Nov 1. Cell Biol Int. 2009. PMID: 18996214
-
Targeting TACE-dependent EGFR ligand shedding in breast cancer.J Clin Invest. 2007 Feb;117(2):337-45. doi: 10.1172/JCI29518. Epub 2007 Jan 11. J Clin Invest. 2007. PMID: 17218988 Free PMC article.
-
Microparticles of human atherosclerotic plaques enhance the shedding of the tumor necrosis factor-alpha converting enzyme/ADAM17 substrates, tumor necrosis factor and tumor necrosis factor receptor-1.Am J Pathol. 2007 Nov;171(5):1713-23. doi: 10.2353/ajpath.2007.070021. Epub 2007 Sep 14. Am J Pathol. 2007. PMID: 17872973 Free PMC article.
Cited by
-
High shed antigen levels within tumors: an additional barrier to immunoconjugate therapy.Clin Cancer Res. 2008 Dec 15;14(24):7981-6. doi: 10.1158/1078-0432.CCR-08-0324. Clin Cancer Res. 2008. PMID: 19088013 Free PMC article. Review.
-
Expression of tumor necrosis factor-alpha converting enzyme in liver regeneration after partial hepatectomy.World J Gastroenterol. 2008 Mar 7;14(9):1353-7. doi: 10.3748/wjg.14.1353. World J Gastroenterol. 2008. PMID: 18322947 Free PMC article.
-
The role of ADAM17 in tumorigenesis and progression of breast cancer.Tumour Biol. 2016 Dec;37:15359–15370. doi: 10.1007/s13277-016-5418-y. Epub 2016 Sep 22. Tumour Biol. 2016. PMID: 27658778 Review.
-
ADAM17 promotes breast cancer cell malignant phenotype through EGFR-PI3K-AKT activation.Cancer Biol Ther. 2009 Jun;8(11):1045-54. doi: 10.4161/cbt.8.11.8539. Epub 2009 Jun 25. Cancer Biol Ther. 2009. PMID: 19395875 Free PMC article.
-
Effects of tetrandrine on glioma cell malignant phenotype via inhibition of ADAM17.Tumour Biol. 2014 Mar;35(3):2205-10. doi: 10.1007/s13277-013-1293-y. Epub 2013 Nov 3. Tumour Biol. 2014. PMID: 24185966
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous